TPI-287: A Comprehensive Analysis of a CNS-PenetrANT Abeotaxane for the Treatment of Brain Malignancies

Executive Summary

TPI-287 is an investigational, third-generation, semi-synthetic small molecule belonging to the novel abeotaxane class of microtubule inhibitors. Identified by DrugBank ID DB17168 and CAS Number 849213-15-6, it was specifically engineered to address a long-standing challenge in oncology: the effective treatment of central nervous system (CNS) malignancies. The primary innovation of TPI-287 lies not in its mechanism of action—which mirrors that of conventional taxanes like paclitaxel by stabilizing microtubules, inducing mitotic arrest, and promoting apoptosis—but in its unique pharmacokinetic properties. Structural modifications to its core ring system allow TPI-287 to evade the P-glycoprotein and other efflux pumps that constitute the blood-brain barrier (BBB). This critical feature, extensively validated in preclinical models, enables the drug to achieve and sustain therapeutic concentrations within the brain, a feat that has historically eluded the entire taxane class.

The most compelling clinical evidence for TPI-287's potential comes from a Phase 1/2 study in patients with recurrent glioblastoma multiforme (rGBM), a disease with a profoundly poor prognosis. When administered in combination with the anti-angiogenic agent bevacizumab, TPI-287 demonstrated a remarkable objective response rate of 60% and a median overall survival of approximately 13.4 months, comparing favorably to historical controls. The combination was generally well-tolerated, with a predictable safety profile consistent with the taxane class. Further clinical investigations have explored TPI-287 in pediatric CNS tumors and brain metastases, supported by its Orphan Drug Designations for gliomas and pediatric neuroblastoma.

The drug's development has followed a complex trajectory, originating with Tapestry Pharmaceuticals and progressing through Cortice Biosciences before being strategically in-licensed by CNS Pharmaceuticals in 2024. This recent acquisition has renewed focus on its development for rGBM, with plans for a potential registration study. An exploratory program in neurodegenerative diseases, while ultimately unsuccessful due to population-specific toxicities, provided valuable safety data and reinforced the drug's primary therapeutic potential in neuro-oncology. TPI-287 currently represents one of the most promising late-stage, CNS-penetrant cytotoxic agents for the treatment of aggressive brain cancers.

I. Introduction: A New Generation of Taxane Therapy

The development of TPI-287 represents a targeted and innovative approach to overcoming one of the most formidable obstacles in modern medicine: the delivery of effective therapeutics across the blood-brain barrier (BBB) for the treatment of central nervous system (CNS) malignancies. This section defines the chemical and structural identity of TPI-287, distinguishes it from its predecessors by its classification as an abeotaxane, and frames the critical unmet need in neuro-oncology that it was specifically designed to address.

1.1. Chemical and Structural Identity of TPI-287

TPI-287 is an investigational small molecule drug, cataloged under DrugBank Accession Number DB17168 and CAS Number 849213-15-6.[1] It is a semi-synthetic derivative of naturally occurring taxanes, which are originally isolated from the bark of the yew tree (genus

Taxus).[2] As a third-generation taxane, its structure has been deliberately modified to enhance its pharmacological properties.[5]

The molecular formula of TPI-287 is C46​H63​NO15​, corresponding to a molecular weight of approximately 869.99 g/mol.[6] Its complex chemical structure is formally described by the IUPAC name (1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate.[6] Throughout its development, it has also been known by the synonyms ARC-100 and NBT-287.[6]

Physicochemical predictions highlight its high lipophilicity, with a calculated logP value ranging from 4.03 to 4.65, and a correspondingly low aqueous solubility of 0.00868 mg/mL.[1] These properties are instrumental to its ability to traverse lipid membranes but also necessitate specialized formulation for intravenous administration. Notably, with a molecular weight exceeding 500 g/mol and a high number of hydrogen bond acceptors (10), TPI-287 violates several of Lipinski's "Rule of Five" criteria for oral bioavailability, though this is less relevant for an intravenously administered agent and is superseded by its unique transport characteristics across the BBB.[1]

Property	Value	Source(s)
Generic Name	TPI-287	1
DrugBank ID	DB17168	1
CAS Number	849213-15-6	1
Type	Small Molecule	1
Chemical Formula	C46​H63​NO15​	6
Molecular Weight	869.99 g/mol	6
IUPAC Name	(1S,2S,4S,7S,7aR,7a1S,10aS,11aR,13aS,13bR)-1-(benzoyloxy)-4-(((2R,3S)-3-((tert-butoxycarbonyl)amino)-2-hydroxy-5-methylhexanoyl)oxy)-2-hydroxy-5,7a1,14,14-tetramethyl-9-vinyl-2,3,4,7,7a,7a1,10a,11,11a,13,13a,13b-dodecahydro-1H-8,10,12-trioxa-2,6-methanocyclobuta[b]cyclodeca[de]naphthalene-7,13a-diyl diacetate	6
Synonyms	ARC-100, NBT-287	6
Water Solubility	0.00868 mg/mL	1
logP	4.03 - 4.65	1
Polar Surface Area	211.68 A˚2	1
Rule of Five Violation	Yes	1

1.2. The Abeotaxane Class: A Structural Departure from Conventional Taxanes

TPI-287 is a member of the taxane diterpenoid (taxoid) family, but it is further distinguished by its classification within the novel abeotaxane subclass.[2] This classification is not merely academic; it signifies a fundamental alteration of the core chemical scaffold that defines the taxane family. Conventional taxoids, such as the widely used chemotherapeutics paclitaxel and docetaxel, are characterized by a core ring structure composed of a 6-membered A ring, an 8-membered B ring, and a 6-membered C ring (a 6/8/6 system).[11]

Abeotaxanes, in contrast, possess a rearranged core skeleton with a 5-membered A ring, a 7-membered B ring, and a 6-membered C ring, resulting in a 5/7/6 type ring structure.[11] This structural rearrangement is a key design element, intended to confer new pharmacological properties upon the molecule. Specifically, this alteration is believed to be responsible for TPI-287's ability to circumvent the multidrug resistance (MDR) mechanisms that limit the efficacy of its conventional taxane predecessors.[3]

1.3. The Unmet Need in Neuro-Oncology: Overcoming the Blood-Brain Barrier

The development of TPI-287 was driven by a persistent and critical failure in cancer therapy. Glioblastoma multiforme (GBM) stands as the most common and lethal primary brain tumor in adults, with a median survival of only months in the recurrent setting, highlighting a profound unmet medical need for effective treatments.[12] The taxane class of drugs, including paclitaxel and docetaxel, are among the most powerful and widely used chemotherapeutic agents against a broad spectrum of solid tumors.[2] Their mechanism of action, the stabilization of microtubules, is a proven strategy for inducing cell death in rapidly dividing cancer cells.

However, the entire taxane class has been historically ineffective in treating brain tumors.[2] The reason for this failure is the blood-brain barrier (BBB), a highly specialized and selective physiological barrier that protects the CNS from toxins and pathogens.[15] A key component of the BBB is a family of ATP-binding cassette (ABC) transporters, or efflux pumps, such as P-glycoprotein (P-gp), which actively recognize and expel a wide range of xenobiotics from the brain endothelial cells back into the bloodstream.[15] Conventional taxanes are potent substrates for these pumps, meaning that even if they passively diffuse into the BBB, they are immediately and efficiently removed, preventing them from ever reaching therapeutic concentrations within the brain parenchyma.[2]

TPI-287 represents a purpose-built solution to this pharmacological problem. Its unique abeotaxane structure and other modifications were specifically designed to render it a poor substrate for these efflux pumps.[2] By evading P-gp-mediated efflux, TPI-287 is able to bypass this key defense mechanism of the BBB, allowing it to penetrate the CNS and accumulate within brain tissue.[2] This property is the central innovation of TPI-287 and forms the entire basis of its therapeutic rationale for brain malignancies. It is not simply a new taxane; it is a taxane engineered to deliver a proven cytotoxic mechanism to a pharmacologically protected sanctuary site.

II. Preclinical Profile and Pharmacological Rationale

The preclinical evaluation of TPI-287 established the fundamental basis for its progression into human clinical trials. This body of research confirmed its mechanism of action as a potent microtubule stabilizer, demonstrated its ability to overcome common drug resistance pathways, and, most critically, provided definitive evidence of its capacity to penetrate the blood-brain barrier and exert antitumor effects in CNS tumor models.

2.1. Mechanism of Action: Microtubule Stabilization and Induction of Apoptosis

The antineoplastic activity of TPI-287 is derived from its function as a microtubule-stabilizing agent, a mechanism it shares with all members of the taxane class.[5] Microtubules are essential components of the cellular cytoskeleton, composed of polymers of the protein tubulin. They are highly dynamic structures, constantly undergoing assembly (polymerization) and disassembly (depolymerization) to facilitate critical cellular processes, most notably the segregation of chromosomes during mitosis.[2]

TPI-287 exerts its effect by binding directly to tubulin within the microtubule polymer.[5] This binding event stabilizes the structure, effectively locking it in a polymerized state and preventing the necessary depolymerization required for mitotic progression.[2] By inhibiting these microtubule dynamics, TPI-287 disrupts the formation and function of the mitotic spindle, the cellular machinery responsible for separating replicated chromosomes into two new daughter cells.[8] This interference causes a halt in the cell cycle, specifically at the G2/M transition phase.[5] Cells arrested in mitosis for a prolonged period ultimately activate intrinsic cell death pathways, leading to apoptosis.[5] This induction of programmed cell death in rapidly dividing cancer cells is the ultimate source of TPI-287's therapeutic effect.

Furthermore, preclinical investigations have shown that TPI-287 can act synergistically with other anticancer agents. In glioblastoma cell models, combining TPI-287 with an Aurora-A kinase (AURKA) inhibitor, alisertib, led to a potent synergistic induction of apoptosis. This combination was found to be more effective at preventing "mitotic slippage," a phenomenon where cancer cells escape a mitotic block and survive, thereby committing a greater majority of tumor cells to apoptosis.[8]

2.2. Pharmacodynamics: In Vitro Cytotoxicity and Potency Analysis

In vitro studies confirmed that TPI-287 possesses potent cytotoxic activity comparable to that of established microtubule-stabilizing agents, including paclitaxel and the epothilones.[15] A key design feature of TPI-287, however, was its intended ability to overcome the mechanisms of multidrug resistance (MDR) that often render conventional taxanes ineffective. This was achieved through specific modifications to the taxane side chain and the baccatin ring structure, which were intended to circumvent MDR-based resistance and enable binding to mutant forms of tubulin.[3]

This design proved successful in cell-based assays. TPI-287 demonstrated significant activity against a panel of cancer cell lines known to be resistant to standard taxanes, including those derived from breast, colon, and prostate cancers.[4] The potency difference was often dramatic; in MDR-positive (MDR+) cell lines, TPI-287 was found to be 5- to 3900-fold more active than various comparator drugs. In one specific example, using the MDR+ MCF-7-AR breast cancer cell line, TPI-287 was 20 times more active than paclitaxel, underscoring its ability to evade common resistance pathways.[4]

2.3. Pharmacokinetics: Preclinical Evidence of Blood-Brain Barrier Penetration and CNS Accumulation

The most defining characteristic of TPI-287, and the primary rationale for its development in neuro-oncology, is its demonstrated ability to cross the BBB. This feature was rigorously established in multiple preclinical animal models.[2] As a highly lipophilic molecule that is not a substrate for the P-gp efflux pump, TPI-287 is uniquely equipped to penetrate and accumulate in the CNS following systemic administration.[8]

Pharmacokinetic studies in rodents provided clear, quantitative evidence of this property. Following a single intravenous (IV) injection of 20 mg/kg, the concentration of TPI-287 in the brain was found to progressively exceed that in the plasma over time. The brain-to-plasma concentration ratio, a key metric of CNS penetration, increased steadily, reaching a remarkable peak of 14.1 in rats and 63.8 in mice at 96 hours after the dose was administered.[15] This indicates not only efficient entry into the brain but also prolonged retention within the target tissue. Further analysis in mice revealed a mean residence time for TPI-287 that was more than twice as long in the brain (42.5 hours) as in the plasma (17.6 hours), confirming sustained drug exposure at the site of action.[21]

Crucially, this CNS accumulation was shown to translate into significant therapeutic activity. In a highly aggressive mouse model of breast cancer brain metastasis, TPI-287 treatment significantly reduced the metastatic colonization of the brain by 55%. In the same model, paclitaxel, unable to cross the BBB, had no effect.[15] Similarly, in an orthotopic xenograft model using the human U251 glioblastoma cell line, TPI-287 monotherapy increased the survival of the animals. When combined with temozolomide, the standard-of-care alkylating agent for GBM, TPI-287 produced a powerful synergistic effect, increasing the percent increase in lifespan (%ILS) to 650%, compared to 400% for temozolomide alone.[21]

The combination of these preclinical findings established a compelling, two-pronged rationale for advancing TPI-287 into clinical trials for recurrent brain tumors. Recurrent disease is defined by its location within the pharmacologically protected CNS and by its inherent or acquired resistance to first-line therapies. The preclinical data strongly suggested that TPI-287 was uniquely capable of addressing both of these challenges simultaneously: its BBB penetrance allows it to reach the tumor, and its ability to overcome MDR allows it to effectively kill chemoresistant cells. This dual capability makes it a particularly strong candidate for the difficult-to-treat recurrent setting.

III. Clinical Development in Oncology

The clinical development program for TPI-287 has been extensive, spanning more than 350 patients across multiple trials, sponsors, and indications.[2] While its potential has been explored in various solid tumors and even neurodegenerative diseases, the most compelling and therapeutically relevant data have emerged from its investigation in CNS malignancies, particularly recurrent glioblastoma multiforme (rGBM). This section provides a detailed analysis of the human clinical trials that have shaped the current understanding of TPI-287's efficacy and safety profile in oncology.

NCT Identifier	Phase	Condition(s)	Status (as of last update)	Sponsor(s)	Intervention(s) & Dosing Regimen	Patient Population (N)	Key Efficacy Outcomes	Key Safety Findings / MTD
NCT01933815 / NCT01582152	1/2	Recurrent Glioblastoma (rGBM)	Terminated / Suspended	Cortice Biosciences / M.D. Anderson Cancer Center	TPI-287 (140-220 mg/m2 IV q3w) + Bevacizumab (10 mg/kg IV q2w)	24	ORR: 60%; DCR: 96%; mPFS: 5.5 mo; mOS: 13.4 mo	Well-tolerated; No DLTs; MTD not reached; Optimal Phase 2 dose: 200 mg/m2
NCT00867568	1	Refractory/Recurrent Neuroblastoma or Medulloblastoma	Completed	Giselle Sholler / Archer Biosciences	TPI-287 monotherapy & in combination with Temozolomide	Not specified	Tumor response was secondary objective	Well-tolerated in pediatric population
NCT01332630	2	Breast Cancer Metastatic to the Brain	Completed	M.D. Anderson Cancer Center	TPI-287 (Starting dose 160 mg/m2 IV)	Up to 69	Efficacy in controlling brain metastases	Primary objective was to determine MTD
NCT00256191 / NCT00113724	1	Advanced Malignancies (Solid Tumors, Lymphoma)	Completed	Cortice Biosciences / Tapestry Pharmaceuticals	TPI-287 IV q21d dose escalation	~48	Antitumor activity was secondary objective	Primary objective was to determine MTD

3.1. Recurrent Glioblastoma Multiforme (rGBM): The Cornerstone Indication

The investigation of TPI-287 in rGBM represents the most advanced and promising area of its clinical development. This patient population faces a dismal prognosis, with no established standard of care and median survival measured in months, creating a significant unmet need for novel therapeutic agents.[12]

3.1.1. Analysis of Phase 1/2 Trials in Combination with Bevacizumab

The cornerstone evidence for TPI-287 in rGBM comes from a multi-center Phase 1/2 trial, known as CB-017 (associated with NCT01933815), which evaluated the drug in combination with bevacizumab.[12] Bevacizumab (Avastin®) is a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and is approved for use in rGBM.[28] The trial enrolled patients with rGBM at their first or second relapse who had not previously been treated with an anti-angiogenic agent.[12]

The Phase 1 portion of the study employed a classic 3+3 dose-escalation design to establish the safety and determine the maximum tolerated dose (MTD) of the combination.[12] A total of 24 patients were enrolled across six U.S. centers into seven dose cohorts, receiving TPI-287 at doses ranging from 140

mg/m2 to 220 mg/m2 via IV infusion every three weeks. This was administered concurrently with a standard dose of bevacizumab at 10 mg/kg every two weeks.[12] A separate Phase 1/2 adaptive randomized trial (NCT01582152) was initiated at M.D. Anderson Cancer Center to compare bevacizumab alone with the combination, but its Phase 2 portion was ultimately terminated to avoid competing with the sponsor-led CB-017 study.[31]

3.1.2. Efficacy Endpoints: Objective Response Rate, Progression-Free Survival, and Overall Survival vs. Historical Controls

Despite being a safety-focused Phase 1 study, the CB-017 trial produced remarkably strong signals of clinical efficacy.[2] Among the 20 to 23 patients evaluable for response and survival, the results were highly encouraging:

• Objective Response Rate (ORR): The combination achieved an ORR of 60%. This included 3 patients (15%) with a complete response (CR), where all signs of the tumor disappeared, and 9 patients (45%) with a partial response (PR).[20]
• Disease Control Rate (DCR): The DCR, which includes patients with a CR, PR, or stable disease (SD), was 96%, indicating that nearly all patients derived some clinical benefit from the treatment.[2]
• Progression-Free Survival (PFS): The median PFS was 5.5 months, with 37-40% of patients remaining progression-free at the 6-month mark.[12]
• Overall Survival (OS): The median OS was 13.4 months, and the 12-month overall survival rate was 64%.[12]

These outcomes are notable as they compare very favorably to historical data for bevacizumab-based therapies in similar rGBM populations. Landmark studies of bevacizumab, either as a monotherapy or in combination with chemotherapy, typically report a median PFS of 3 to 4 months and a median OS of 7 to 9 months.[2] The substantial improvement seen with the addition of TPI-287 suggests a potent therapeutic contribution from the CNS-penetrant taxane.

The observed efficacy may be explained by a powerful synergistic interaction between the two drugs. Bevacizumab, as an anti-angiogenic agent, primarily targets the highly vascularized core of the tumor, normalizing blood vessels and reducing edema.[12] However, its major limitation is its lack of activity against the highly motile, infiltrative glioma cells that migrate along white matter tracts into the surrounding brain parenchyma, which are the primary drivers of recurrence.[35] TPI-287, by virtue of its ability to cross the BBB, is theoretically capable of reaching these disseminated, infiltrative cells that are beyond the reach of bevacizumab's anti-vascular effects. This complementary, dual mechanism—bevacizumab controlling the tumor core and TPI-287 targeting the migratory periphery—likely accounts for the high response rates and favorable survival outcomes observed in the trial.

3.1.3. Safety and Tolerability in the rGBM Patient Population

The combination of TPI-287 and bevacizumab was found to be safe and generally well-tolerated.[2] In the Phase 1 dose-escalation study, no dose-limiting toxicities (DLTs) were reported, even at the highest dose level of 220

mg/m2.[12] Consequently, a formal MTD was not reached. The investigators chose to halt dose escalation at 220

mg/m2 due to an increasing frequency of low-grade, manageable side effects, particularly myelosuppression and peripheral neuropathy, which are known, predictable class effects of taxane chemotherapy.[20]

The most common treatment-emergent adverse events were consistent with the known profiles of both taxanes and bevacizumab. These included fatigue, myelosuppression (specifically neutropenia), and peripheral sensory neuropathy.[12] The only drug-related Grade 3/4 adverse event noted in one report was myelosuppression, affecting three patients.[20] Based on the balance of observed efficacy and the emerging, albeit low-grade, toxicity profile, an independent clinical advisory board determined the optimal Phase 2 dose (OP2D) to be 200

mg/m2.[12]

3.2. Pediatric CNS Malignancies: Neuroblastoma and Medulloblastoma

Recognizing the potential for a CNS-penetrant cytotoxic agent in pediatric brain tumors, TPI-287 was evaluated in a Phase 1 trial (NCT00867568) for children and young adults with refractory or recurrent neuroblastoma or medulloblastoma.[4] This was a critical step, as it represented the first clinical testing of TPI-287 in a pediatric population.[4] The study design was based on strong preclinical data showing TPI-287's high potency against neuroblastoma cell lines and xenograft models, as well as a synergistic or additive effect when combined with temozolomide.[4] The trial assessed TPI-287 both as a monotherapy and in combination with temozolomide and found that the drug was well-tolerated.[8] In recognition of its potential in this rare disease, the U.S. Food and Drug Administration (FDA) granted TPI-287 an Orphan Drug Designation for the treatment of pediatric neuroblastoma.[33]

3.3. Metastatic Brain Cancers

The compelling preclinical data showing TPI-287's unique ability to reduce brain metastatic colonization from breast cancer cells, where paclitaxel failed, provided a direct rationale for human studies in this setting.[15] A Phase 2 open-label study (NCT01332630) was subsequently initiated by the M.D. Anderson Cancer Center to evaluate the safety, tolerability, and efficacy of TPI-287 in patients with breast cancer that had metastasized to the brain.[37] The study protocol involved intravenous administration of TPI-287 with standard premedication (dexamethasone, diphenhydramine, and ranitidine) to mitigate the risk of hypersensitivity reactions commonly associated with taxane formulations.[37] The primary goals were to establish a safe and tolerable dose and to assess the drug's ability to control CNS disease in this patient population.[37]

IV. Clinical Exploration in Neurodegenerative Disease

In a significant departure from its development in oncology, TPI-287 was also investigated as a potential therapeutic for neurodegenerative disorders known as tauopathies. This program, while ultimately discontinued due to safety concerns, yielded critical data on the drug's tolerability in a non-cancer population and provided valuable insights that have helped to refine its overall development strategy.

4.1. Rationale for Microtubule Stabilization in Tauopathies

A range of neurodegenerative conditions, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS), are pathologically linked by the abnormal aggregation of the microtubule-associated protein tau.[2] In a healthy neuron, tau binds to and stabilizes microtubules, which are crucial for maintaining cell structure and facilitating axonal transport. In tauopathies, tau becomes hyperphosphorylated and detaches from microtubules, leading to microtubule instability and the formation of neurofibrillary tangles, which are hallmarks of the disease.[39] This disruption of the microtubule network impairs neuronal function and contributes to cell death.

The therapeutic hypothesis was that a CNS-penetrant microtubule-stabilizing agent like TPI-287 could pharmacologically compensate for the loss of function of pathological tau. By directly stabilizing the microtubule network, it was thought that TPI-287 might restore neuronal integrity and function, potentially slowing or even reversing the neurodegenerative process.[38] This rationale was supported by laboratory studies in mouse models of tauopathy where similar agents had shown improvements in cognitive performance.[39]

4.2. Analysis of Phase 1 Trials in Alzheimer's Disease, PSP, and CBS

To test this hypothesis, placebo-controlled, double-blinded Phase 1 clinical trials were conducted to evaluate the safety, tolerability, and pharmacodynamics of TPI-287.[38] One such study, NCT01966666, enrolled patients with mild-to-moderate AD as well as patients with 4-repeat tauopathies (4RT), which include PSP and CBS.[40]

The study used a multiple ascending dose design, with patients randomized to receive either TPI-287 or placebo. Three sequential cohorts were treated with intravenous infusions of TPI-287 at 2.0 mg/m2, 6.3 mg/m2, or 20.0 mg/m2 once every three weeks for a total of four infusions over nine weeks.[38] While the primary endpoints were safety and tolerability, the studies also included exploratory assessments of cognitive function (e.g., Mini-Mental State Exam) and cerebrospinal fluid (CSF) biomarkers of inflammation (e.g., YKL-40).[38]

4.3. Divergent Safety Profile: Anaphylactoid Reactions and Tolerability Challenges

The results from the neurodegeneration program revealed a stark and unexpected divergence in the safety profile of TPI-287 compared to what had been observed in oncology patients. The most alarming finding was the occurrence of three severe, life-threatening anaphylactoid reactions in patients with AD who were treated with TPI-287.[38] Critically, these severe hypersensitivity reactions were not observed in the cohort of patients with 4RT (PSP/CBS).[38]

This population-specific toxicity had immediate and significant consequences for the trial. It led to the establishment of a much lower MTD for the AD population (6.3 mg/m2) compared to the 4RT population (20.0 mg/m2).[38] In addition to the anaphylactoid reactions, other adverse events were more prevalent in the treatment groups, including a higher number of falls and a dose-related worsening of dementia symptoms compared to placebo.[38]

Another perplexing finding from these studies was that despite the strong preclinical evidence of BBB penetration, TPI-287 levels were undetectable in the CSF of treated patients.[38] While CSF concentration is not always a perfect surrogate for brain tissue concentration, this result raised questions about the extent of CNS exposure achieved at the very low doses used in these trials, which were an order of magnitude lower than the doses used in the GBM studies.

The dramatic difference in tolerability between the elderly AD population and the heavily pre-treated cancer patient population was a pivotal finding. While the oncology trials demonstrated manageable, predictable taxane-class toxicities at doses up to 220 mg/m2, the AD trials revealed life-threatening hypersensitivity at doses as low as 6.3 mg/m2. This suggests a fundamental interaction between the drug (or its formulation vehicle, as taxanes are often formulated with Cremophor EL, a known cause of hypersensitivity) and the specific pathophysiology of AD, the comorbidities of this elderly population, or their altered drug metabolism. This severe and unpredictable safety signal effectively halted further development of TPI-287 for neurodegenerative diseases and firmly refocused its future on oncology, where the risk-benefit assessment is vastly different and where its tolerability at therapeutically relevant doses has been well-established.

V. Consolidated Safety and Tolerability Assessment

A comprehensive understanding of TPI-287's safety profile requires a synthesis of data collected across its diverse clinical programs, which have involved over 350 patients with varying underlying diseases, ages, and co-morbidities.[2] This assessment reveals a profile characterized by typical taxane-class effects in oncology settings but also highlights critical population-specific toxicities that have been instrumental in guiding its development path.

5.1. Common Taxane-Related Adverse Events Across Trials

In the context of oncology, TPI-287 has consistently demonstrated a safety profile that aligns with other microtubule-active agents of the taxane class.[2] The most frequently reported treatment-emergent adverse events across studies in glioblastoma, neuroblastoma, and other advanced malignancies are predictable and manageable. These include:

• Myelosuppression: A reduction in bone marrow function, leading primarily to neutropenia (low white blood cell counts). This was the only drug-related Grade 3/4 adverse event reported in one summary of the pivotal GBM trial.[20]
• Peripheral Sensory Neuropathy: Numbness, tingling, or pain, typically in the hands and feet, is a well-known cumulative toxicity of taxanes.[12]
• Fatigue: A common side effect of cytotoxic chemotherapy.[12]

These side effects generally appear to be dose-related. In the rGBM dose-escalation trial, an increased frequency of low-grade myelosuppression and neuropathy was observed in the cohorts receiving the highest doses of TPI-287, which ultimately led to the decision to halt further escalation.[20]

5.2. Dose-Limiting Toxicities and Maximum Tolerated Dose Determinations

The determination of the MTD for TPI-287 has varied dramatically depending on the patient population being studied, underscoring the importance of context in safety evaluation.

• Oncology Population (rGBM): In the Phase 1 trial combining TPI-287 with bevacizumab for rGBM, no formal DLTs were encountered even at the highest dose of 220 mg/m2. Therefore, the MTD was not officially reached.[12] The study team, in consultation with an advisory board, selected 200 mg/m2 as the optimal dose for future Phase 2 studies, balancing the strong efficacy signals with the emergence of manageable, low-grade taxane-related toxicities at the highest dose levels.[12]
• Neurodegenerative Disease Population: In stark contrast, the trials in elderly patients with tauopathies were defined by severe toxicities at much lower doses. In patients with Alzheimer's disease, severe anaphylactoid reactions were considered DLTs, establishing a low MTD of just 6.3 mg/m2. In the 4RT population (PSP/CBS), which did not experience these reactions, a higher MTD of 20.0 mg/m2 was determined.[38]

5.3. Comparative Safety Insights Between Oncologic and Neurologic Patient Cohorts

The comparison between the oncology and neurology programs provides the most critical safety insight for TPI-287. The drug exhibits a vastly more favorable risk-benefit profile in cancer patients, who are often younger and for whom the potential benefits of a life-extending therapy outweigh the risks of manageable chemotherapy side effects. The occurrence of unpredictable, life-threatening hypersensitivity reactions specifically within the AD cohort was a definitive safety signal that has shaped the drug's subsequent development.[38]

Overall, within its intended therapeutic area of neuro-oncology, TPI-287 is described by its developers as being well-tolerated and possessing a favorable safety profile.[33] The adverse events are consistent with its drug class, appear to be dose-dependent, and have been manageable in clinical trial settings.

VI. Corporate and Regulatory Trajectory

The development path of TPI-287 has been long and has involved several corporate entities, reflecting the challenges and persistence required to advance a novel therapeutic, particularly in a difficult field like neuro-oncology. Its recent acquisition by a specialized company and its collection of key regulatory designations have created a clear and promising path forward.

6.1. Developmental History: From Tapestry Pharmaceuticals to Cortice Biosciences

The journey of TPI-287 began at Tapestry Pharmaceuticals, Inc., where the novel abeotaxane was first developed with the specific intent of creating a taxane analog that could overcome multidrug resistance.[3] Early clinical trials, such as NCT00256191 for advanced malignancies, were sponsored by Tapestry.[3] Subsequently, sponsorship for some pediatric trials, including NCT00867568 in neuroblastoma, was taken up by Archer Biosciences, Inc..[4]

For the most significant period of its recent clinical evaluation, including the pivotal Phase 1/2 trial in rGBM (CB-017) and the Phase 1 studies in neurodegenerative diseases, the drug was under the stewardship of Cortice Biosciences, Inc..[35] It was under Cortice's sponsorship that the compelling efficacy data in glioblastoma and the critical safety signals in Alzheimer's disease were generated.

6.2. Strategic In-Licensing by CNS Pharmaceuticals: A Renewed Focus

A pivotal moment in the drug's history occurred in July 2024, when CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a clinical-stage biopharmaceutical company with a dedicated focus on developing treatments for cancers of the brain and CNS, announced an exclusive licensing agreement for TPI-287 with Cortice Biosciences.[25] This transaction granted CNS Pharmaceuticals the intellectual property rights and the responsibility for all future development and commercialization of TPI-287 in key markets, including the United States, Canada, Mexico, and Japan.[25]

The leadership at CNS Pharmaceuticals has described this in-licensing as a "transformational" event for the company.[25] TPI-287 is now positioned as a lead pipeline asset, complementary to their other CNS-penetrant drug candidate, Berubicin. This acquisition represents a critical inflection point, moving a promising but perhaps under-resourced asset into the hands of a specialized, publicly-traded company with the stated intention and existing infrastructure to drive it toward registration. After years of fragmented progress across smaller entities, this strategic alignment could significantly accelerate TPI-287's development.

6.3. Current Development Plan and Future Clinical Strategy for GBM

Following the acquisition, CNS Pharmaceuticals has articulated a clear and aggressive development strategy centered on rGBM, the indication with the strongest existing clinical data.[36] The company's immediate plans include:

• Regulatory Engagement: Engaging with the U.S. FDA in 2025 to discuss the clinical data to date and to gain feedback on the optimal design for a potential registration-enabling study in rGBM.[25]
• Leveraging Existing Infrastructure: Utilizing the global clinical trial network and operational experience established during the development of their other drug, Berubicin, to expedite the initiation of new trials for TPI-287 in a time- and cost-effective manner.[25]
• Initiation of a New Phase 2 Study: The company has publicly stated its goal to commence patient enrollment for a new Phase 2 study in rGBM around the end of 2025 or in the first half of 2026.[36]

6.4. Analysis of FDA Orphan Drug Designations and Their Implications

TPI-287 has successfully secured several Orphan Drug Designations from the FDA. This regulatory status is granted to drugs intended to treat rare diseases, defined in the U.S. as those affecting fewer than 200,000 people.[33] The designations for TPI-287 cover:

• Gliomas: Encompassing high-grade tumors like glioblastoma.[33]
• Pediatric Neuroblastoma: A rare childhood cancer.[33]
• Progressive Supranuclear Palsy (PSP): A rare neurodegenerative tauopathy.[33]

These designations are highly valuable and provide significant strategic advantages for drug development. They confer a number of incentives, including a potential seven-year period of market exclusivity upon drug approval, tax credits for qualified clinical testing, and a waiver of FDA application fees.[36] The granting of these designations serves as a regulatory acknowledgment of the significant unmet medical need in these conditions and of TPI-287's potential to provide a meaningful therapeutic benefit. This status de-risks the development program to some extent and creates a more favorable commercial and regulatory pathway toward potential approval.

VII. Concluding Analysis and Future Perspectives

TPI-287 has emerged from a long and complex development history as a uniquely promising therapeutic candidate for neuro-oncology. Its profile is defined by a combination of a proven cytotoxic mechanism and a novel pharmacokinetic property that allows it to overcome the most significant barrier to treating brain cancer. A comprehensive assessment of its strengths, weaknesses, and future opportunities provides a clear picture of its potential role in the clinical landscape.

7.1. Synthesis of Evidence: TPI-287's Position in the Neuro-Oncology Landscape

TPI-287's primary value proposition is its status as a CNS-penetrant taxane. It effectively delivers a well-understood and potent anti-mitotic mechanism of action into a pharmacologically protected sanctuary. The failure of conventional taxanes in brain cancer has not been due to a lack of efficacy at the cellular level, but purely a failure of drug delivery. TPI-287 appears to have solved this delivery problem.

The clinical data from the Phase 1 study in rGBM, while based on a small number of patients, are highly compelling. The 60% objective response rate and a median overall survival exceeding one year in a bevacizumab-naïve, recurrent population represent a significant signal of activity that stands out against the bleak outcomes typically seen in this disease. The apparent synergy with bevacizumab suggests a powerful combination strategy that targets both the vascular and infiltrative components of glioblastoma. With its recent acquisition by CNS Pharmaceuticals, the drug now has a clear and focused path forward in its most promising indication.

7.2. Critical Assessment of Strengths, Weaknesses, Opportunities, and Threats (SWOT)

A balanced analysis of TPI-287 reveals the following key factors:

• Strengths:
• Strong Mechanistic Rationale: Combines a proven cytotoxic mechanism (microtubule stabilization) with a solution to a historical delivery problem (BBB penetration).
• Compelling Early Clinical Data: The Phase 1 results in rGBM show a strong efficacy signal (high ORR, favorable OS) in a high-unmet-need population.
• Favorable Regulatory Status: Multiple Orphan Drug Designations from the FDA provide significant development and commercial incentives.
• Established Safety Profile in Oncology: In over 350 patients, the safety profile in cancer indications is well-characterized, predictable, and consistent with the taxane class.
• Weaknesses:
• Small Sample Sizes: The most promising efficacy data comes from a Phase 1 study with only 24 patients, which carries the inherent risk of not being replicated in larger trials.
• Unexplained Population-Specific Toxicity: The severe anaphylactoid reactions observed exclusively in the Alzheimer's disease cohort remain a mechanistic question mark, even if that indication is no longer pursued.
• Fragmented Development History: The drug's long journey through multiple smaller companies may have resulted in a less-than-optimal or delayed development strategy prior to its recent acquisition.
• Formal MTD Not Established in GBM: While a safe and effective dose was identified, the lack of a formal MTD in the key indication could require further clarification in future studies.
• Opportunities:
• Clear Registration Pathway: Under the focused stewardship of CNS Pharmaceuticals, there is a clear opportunity to design and execute a pivotal trial in rGBM aimed at regulatory approval.
• Expansion into Other CNS Cancers: The drug's mechanism and CNS penetration provide a strong rationale for investigating its efficacy in brain metastases from other solid tumors (e.g., breast, lung) and other primary brain tumors.
• Novel Combination Therapies: There is significant potential to explore combinations beyond bevacizumab, including with radiotherapy, temozolomide (as explored in preclinical models), and novel targeted agents.
• Threats:
• Clinical Trial Risk: The primary threat is that the highly promising Phase 1 efficacy results will not be validated in a larger, randomized, and more rigorously controlled Phase 2 or 3 trial.
• Competitive Landscape: The field of neuro-oncology is highly active, with novel immunotherapies, cell therapies, and targeted agents in development that could emerge as superior treatment options.
• Long-Term Toxicity: While the short-term safety profile appears manageable, the potential for unforeseen cumulative or long-term toxicities, particularly neurotoxicity, remains a possibility with any CNS-active agent.

7.3. Recommendations for Future Research and Clinical Trial Design

Based on the available evidence, the path forward for TPI-287 should be focused and strategic:

1. Prioritize a Pivotal Trial in rGBM: The highest priority is the initiation of a well-designed, adequately powered, randomized clinical trial for rGBM. A potential design could compare the combination of TPI-287 (at the 200 mg/m2 dose) plus bevacizumab against a standard-of-care control arm, such as bevacizumab monotherapy or lomustine. Overall survival should be the primary endpoint.
2. Incorporate Biomarker Analysis: Future trials should prospectively incorporate biomarker analysis to identify potential predictors of response. Given the activity seen in patients with unmethylated MGMT promoters—a marker of temozolomide resistance—TPI-287 may have a particular niche in this difficult-to-treat subgroup.[27]
3. Investigate Brain Metastases: A Phase 2 "basket" trial evaluating TPI-287 in patients with brain metastases from various primary tumors (e.g., breast cancer, non-small cell lung cancer, melanoma) is strongly warranted. This would leverage the drug's core strength of BBB penetration and address a growing clinical need.
4. Clarify the Anaphylaxis Mechanism: While not a priority for the oncology program, a non-clinical investigation into the mechanism behind the severe hypersensitivity reactions in the AD population could provide valuable immunological insights and confirm that this risk is confined to that specific population, thereby strengthening the overall safety case for the drug in oncology.

In conclusion, TPI-287 stands as a testament to rational drug design, offering a potential solution to the decades-old problem of delivering taxane chemotherapy to the brain. While clinical development is not without risk, the strength of its preclinical rationale and the compelling nature of its early clinical data in glioblastoma position it as a significant asset with the potential to change the treatment paradigm for patients with CNS malignancies.

Works cited

1. TPI-287: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 25, 2025, https://go.drugbank.com/drugs/DB17168
2. TPI 287 - CNS Pharmaceuticals, accessed September 25, 2025, https://cnspharma.com/our-research/tpi-287
3. NCT00256191 | Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies | ClinicalTrials.gov, accessed September 25, 2025, https://www.clinicaltrials.gov/study/NCT00256191
4. Study Details | NCT00867568 | TPI 287 in Patients With Refractory ..., accessed September 25, 2025, https://clinicaltrials.gov/study/NCT00867568
5. Definition of TPI 287 - NCI Drug Dictionary, accessed September 25, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/taxane-analogue-tpi-287
6. TPI-287 | ARC-100 | CAS#849213-15-6 | taxane - MedKoo Biosciences, accessed September 25, 2025, https://www.medkoo.com/products/5920
7. TPI-287 - TargetMol, accessed September 25, 2025, https://www.targetmol.com/compound/tpi-287
8. The CNS penetrating taxane TPI 287 and the AURKA inhibitor alisertib induce synergistic apoptosis in glioblastoma cells - PubMed Central, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6097628/
9. CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM WHO Grade IV After Failure of Standard First Line Therapy, accessed September 25, 2025, https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-presents-update-from-ongoing-potentially-pivotal-study-of-berubicin-compared-with-lomustine-in-adult-patients-with-recurrent-gbm-who-grade-iv-after-failure-of-standard-first-line-therapy-42163834
10. Cortice Biosciences Transfers Orphan Drug Designations for TPI 287 in, accessed September 25, 2025, https://www.onclive.com/view/cortice-biosciences-transfers-orphan-drug-designations-for-tpi-287-in-brain-cancer-and-cns-diseases
11. Abeotaxane - Wikipedia, accessed September 25, 2025, https://en.wikipedia.org/wiki/Abeotaxane
12. Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma - Oxford Academic, accessed September 25, 2025, https://academic.oup.com/noa/article-pdf/6/1/vdae009/56618340/vdae009.pdf
13. Phase 1 Trial of Tpi 287, A Microtubule Stabilizing Agent, In Combination With Bevacizumab In Adults With Recurrent Glioblastoma - DigitalCommons@TMC, accessed September 25, 2025, https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=2612&context=uthmed_docs
14. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials, accessed September 25, 2025, https://www.mdpi.com/2072-6694/13/8/1795
15. TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells - PMC - PubMed Central, accessed September 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7489285/
16. Taxanes for Cancer - Cleveland Clinic, accessed September 25, 2025, https://my.clevelandclinic.org/health/drugs/24914-taxane
17. Preirradiation paclitaxel in glioblastoma multiforme: efficacy, pharmacology, and drug interactions. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. | Journal of Clinical Oncology - ASCO Publications, accessed September 25, 2025, https://ascopubs.org/doi/10.1200/JCO.1997.15.9.3121
18. Hydrophilic Fluorescent Nanoprodrug of Paclitaxel for Glioblastoma ..., accessed September 25, 2025, https://pubs.acs.org/doi/10.1021/acsomega.9b02588
19. Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma | Neuro-Oncology Advances | Oxford Academic, accessed September 25, 2025, https://academic.oup.com/noa/article/6/1/vdae009/7577744
20. Phase 1/2 trial of bevacizumab plus TPI 287, a brain penetrable anti-microtubule agent, in patients with recurrent glioblastoma. - ASCO Publications, accessed September 25, 2025, https://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.2055
21. TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice. | Cancer Research - AACR Journals, accessed September 25, 2025, https://aacrjournals.org/cancerres/article/67/9_Supplement/1441/534525/TPI-287-crosses-the-blood-brain-barrier-and
22. www.onclive.com, accessed September 25, 2025, https://www.onclive.com/view/cortice-biosciences-transfers-orphan-drug-designations-for-tpi-287-in-brain-cancer-and-cns-diseases#:~:text=TPI%20287%20is%20an%20abeotaxane,cross%20the%20blood%2Dbrain%20barrier.
23. (PDF) Phase 1 Trial of TPI 287, a Microtubule Stabilizing Agent, in Combination with Bevacizumab in Adults with Recurrent Glioblastoma - ResearchGate, accessed September 25, 2025, https://www.researchgate.net/publication/377559962_Phase_1_Trial_of_TPI_287_a_Microtubule_Stabilizing_Agent_in_Combination_with_Bevacizumab_in_Adults_with_Recurrent_Glioblastoma
24. CAS 849213-15-6 TPI-287 - BOC Sciences, accessed September 25, 2025, https://www.bocsci.com/product/tpi-287-cas-849213-15-6-462226.html
25. CNS Pharmaceuticals Expands Pipeline with In License of Late Stage Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies, accessed September 25, 2025, https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-expands-pipeline-with-in-license-of-late-stage-novel-potential-blood-brain-barrier-permeable-abeotaxane-for-treatment-of-brain-malignancies-40033084
26. Recurrent Glioblastoma: A Review of the Treatment Options - MDPI, accessed September 25, 2025, https://www.mdpi.com/2072-6694/15/17/4279
27. Final results from the dose-escalation stage of a phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma. - ASCO, accessed September 25, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT191134
28. Study Details | NCT01582152 | Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | ClinicalTrials.gov, accessed September 25, 2025, https://www.clinicaltrials.gov/study/NCT01582152
29. Avastin® (bevacizumab) Dosing | rGBM Treatment, accessed September 25, 2025, https://www.avastin.com/hcp/rgbm/dosing-usage.html
30. Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma - PubMed, accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/38327681
31. Study Details | NCT01582152 | Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT01582152
32. Record History | NCT01582152 - ClinicalTrials.gov, accessed September 25, 2025, https://www.clinicaltrials.gov/study/NCT01582152?tab=history
33. CNS Pharmaceuticals Presents Brain-Penetrating Taxane TPI 287 for Glioblastoma Treatment at 2025 Brain Tumor Summit - MedPath, accessed September 25, 2025, https://trial.medpath.com/news/269d3db2d4ed8d57/cns-pharmaceuticals-presents-brain-penetrating-taxane-tpi-287-for-glioblastoma-treatment-at-2025-brain-tumor-summit
34. Bevacizumab or Avastin | The Brain Tumour Charity, accessed September 25, 2025, https://www.thebraintumourcharity.org/brain-tumour-diagnosis-treatment/treating-brain-tumours/treatments-licensed-other-illnesses/bevacizumab-avastin/
35. Cortice starts first stage of Phase II TPI 287-Avastin combination trial to treat glioblastoma, accessed September 25, 2025, https://www.clinicaltrialsarena.com/news/newscortice-starts-first-stage-of-phase-ii-tpi-287-avastin-combination-trial-to-treat-glioblastoma-4201177/
36. CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel Late Stage Abeotaxane TPI 287, accessed September 25, 2025, https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-acquires-orphan-drug-designation-for-novel-late-stage-abeotaxane-tpi-287-45371249
37. Study Details | NCT01332630 | TPI 287 in Breast Cancer Metastatic ..., accessed September 25, 2025, https://www.clinicaltrials.gov/study/NCT01332630
38. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients with Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial - WashU Medicine Research Profiles, accessed September 25, 2025, https://profiles.wustl.edu/en/publications/reactions-to-multiple-ascending-doses-of-the-microtubule-stabiliz
39. Cortice Biosciences Announces Presentation of Results from Placebo-Controlled Phase 1 Clinical Trials Evaluating TPI 287 for Treatment of Alzheimer's Disease and Related Tauopathies - GlobeNewswire, accessed September 25, 2025, https://www.globenewswire.com/news-release/2017/11/03/1174533/0/en/Cortice-Biosciences-Announces-Presentation-of-Results-from-Placebo-Controlled-Phase-1-Clinical-Trials-Evaluating-TPI-287-for-Treatment-of-Alzheimer-s-Disease-and-Related-Tauopathie.html
40. NCT01966666 | A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease | ClinicalTrials.gov, accessed September 25, 2025, https://clinicaltrials.gov/study/NCT01966666
41. Alzheimer's Disease (AD) Completed Phase 1 Trials for ... - DrugBank, accessed September 25, 2025, https://go.drugbank.com/indications/DBCOND0049114/clinical_trials/DB17168?phase=1&status=completed
42. Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial - PubMed, accessed September 25, 2025, https://pubmed.ncbi.nlm.nih.gov/31710340/
43. CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme - BioSpace, accessed September 25, 2025, https://www.biospace.com/press-releases/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-second-line-treatment-of-glioblastoma-multiforme
44. Study of TPI 287 in Patients With Advanced Malignancies | ClinicalTrials.gov, accessed September 25, 2025, https://www.clinicaltrials.gov/study/NCT00113724
45. Archer Biosciences, Inc. Announces Initiation of Dosing in 3rd Cohort in Metastatic Melanoma Clinical Trial - BioSpace, accessed September 25, 2025, https://www.biospace.com/archer-biosciences-inc-announces-initiation-of-dosing-in-3rd-cohort-in-metastatic-melanoma-clinical-trial
46. CNS Pharmaceuticals Licenses TPI 287 - Pharma Now, accessed September 25, 2025, https://www.pharmanow.live/latest-news/cns-pharmaceuticals-licenses-tpi-287
47. CNS Pharmaceuticals Reports Full Year 2024 Financial Results, accessed September 25, 2025, https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-reports-full-year-2024-financial-results-44583220
48. CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update, accessed September 25, 2025, https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-reports-second-quarter-2025-financial-results-and-provides-corporate-update-47151944
49. CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | CNSP Stock News, accessed September 25, 2025, https://www.stocktitan.net/news/CNSP/cns-pharmaceuticals-acquires-orphan-drug-designation-for-novel-late-gguckmcwzups.html